Tyrosine kinase inhibitor therapy in chronic myeloid leukemia: update on key adverse events.
about
Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerationsAdvances and challenges in hereditary cancer pharmacogenetics.Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature.
P2860
Tyrosine kinase inhibitor therapy in chronic myeloid leukemia: update on key adverse events.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Tyrosine kinase inhibitor ther ...... update on key adverse events.
@en
type
label
Tyrosine kinase inhibitor ther ...... update on key adverse events.
@en
prefLabel
Tyrosine kinase inhibitor ther ...... update on key adverse events.
@en
P2093
P2860
P1476
Tyrosine kinase inhibitor ther ...... update on key adverse events.
@en
P2093
Benedito A Carneiro
Francis J Giles
Jason B Kaplan
P2860
P304
P356
10.1586/17474086.2015.1041910
P577
2015-05-04T00:00:00Z